SCHEMBL9910015

SCHEMBL9910015

Cc1cc(N)c(C(C)(C)C)cc1-c1ccc(F)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.38
NPC1 O15118 4/20 0.38
RAB9A P51151 4/20 0.38
KMT2A Q03164 4/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
KDM4E B2RXH2 2/20 0.38
MAPT P10636 1/20 0.38
ABL1 P00519 2/20 0.35
PIK3CA P42336 1/20 0.35
PTGS2 P35354 3/20 0.35
PTGS1 P23219 2/20 0.35
ALDH1A1 P00352 1/20 0.34
CYP3A4 P08684 1/20 0.34
TSHR P16473 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
TDO2 P48775 1/20 0.34
LMNA P02545 1/20 0.34
SQOR Q9Y6N5 1/20 0.34
CYP1A1 P04798 1/20 0.33
GCGR P47871 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2698015 0.85 HDAC1 (0.41) MEN1NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL2696067 0.80 SQOR (0.43) MEN1KMT2ASMN1; SMN2KDM4EMAPT
SCHEMBL21938179 0.75 ACHE (0.46) MEN1NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL278779 0.75 PGR (0.42) MEN1KMT2APTGS2PTGS1ALDH1A1
SCHEMBL12148763 0.73 ACHE (0.43) MEN1NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL12933311 0.72 CYP3A4 (0.37) SMN1; SMN2KDM4EMAPTALDH1A1CYP3A4
SCHEMBL22367815 0.71 CYP3A4 (0.50) MEN1KMT2ASMN1; SMN2KDM4EMAPT
SCHEMBL752139 0.70 NPC1 (0.45) MEN1NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL279009 0.70 ALDH1A1 (0.50) MEN1KMT2ASMN1; SMN2KDM4EMAPT
SCHEMBL14443262 0.70 ALDH1A1 (0.44) MEN1KMT2AMAPTPTGS2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198299-B2 Cycloalkylidene and heterocycloalkylidene inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-06-12 US disclosed
US-20120045412-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120045412-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC2 MEN1 4082/4885NPC1 277/4885RAB9A 2514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.